Azanta A/S Welcomes Bo Jesper Hansen as Board Member
Azanta A/S welcomes Bo Jesper Hansen as a member of the Board of Directors and David Kauffmann as the vice-chairman of the Board
Hellerup, Denmark, December 14, 2015.
Today Azanta A/S (“Azanta”) announces that Bo Jesper Hansen has been elected as a member of the Azanta Board of Directors.
Bo Jesper Hansen is Chairman of Sobi AB (Swedish Orphan Biovitrum) a leading integrated biopharmaceutical company with innovative therapies and services, and a diversified and growth-oriented product portfolio. Bo is also Chairman of Karolinska Development and a Board Director of Newron Pharmaceuticals, Genspera Inc., CMC AB, Orphazyme and Ablynx. Formerly, Bo was CEO at Swedish Orphan International and was the founder of Scandinavian Medical Research and co-founder of Swedish Orphan International. Bo holds an M.D. and a Ph.D. from Copenhagen University.
Bo Jesper Hansen was elected as a Board Director of Azanta at the Company’s Extraordinary General meeting on December 01, 2015. Also, at this meeting David Kauffmann was elected as Vice-Chairman and said: “It is my pleasure to welcome Bo Jesper Hansen to the Azanta Board of Directors. We have looked to strengthen the Company’s Board with a person who has the combination of pharma-medical and commercial experience and who knows Specialty Pharma from the inside. Bo has among his many qualities the combination of these traits, which is rare in one person. We are therefore extremely delighted that Bo has agreed to join our Board. We have great confidence that Bo, with his background and experience, will add great value to Azanta.
Bo Jesper Hansen said: “I am happy to join the Board of Azanta. The Company has the opportunity to become an important player in the Specialty Pharma field. I am looking forward to working with the Company’s management in providing innovative medical solutions for patients”.
About Azanta A/S
Azanta A/S (“Azanta”) is a privately owned specialty pharma company primarily operating within oncology, women´s health and addiction medicine. Azanta seeks to be an international market leader within certain specialty pharma product categories, employing innovative repositioning and drug formulation strategies. Azanta currently markets (or makes available under special authorization) a portfolio of specialty pharmaceutical products, including Nimoral™, a hypoxic radiosensitizer for the treatment of head and neck cancer patients undergoing primary radiotherapy and Angusta® for labour induction.
For further information, please visit www.azanta.com.
Hanne Damgaard Jensen – CEO
Tel: + 45 – 70 25 95 45
Fax: + 45 – 70 25 95 46